DELE1 and B-cell chronic lymphocytic leukemia: Notably, PMAIP1 and BAX mutations were recently reported in CLL patients that relapsed on VEN monotherapy.31 Silencing of additional genes, including OMA1, GLUL, KIAA0141, and CHST9 also lead to VEN resistance (Supplementary Fig. 5k).